Japan has cautiously granted a conditional, global-first approval to SanBio Co., Ltd’s autologous mesenchymal stem cell (MSC)-based therapy Akuugo (vandefitemcel; SB623) for traumatic brain injury (TBI), setting the stage for a market debut after development setbacks in other settings.
But regulatory authorities have said the regenerative medicine cannot be marketed until product equivalency between manufacturing batches can be properly...
Welcome to Scrip
Create an account to read this article
Already a subscriber?